Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?

Is PGEN a bully banal to buy? We came crossed a bullish thesis on Precigen, Inc. connected Valueinvestorsclub.com by coalone. In this article, we volition summarize the bulls’ thesis connected PGEN. Precigen, Inc.'s stock was trading astatine $4.0200 arsenic of April 28^th. PGEN’s guardant P/E was 9.14 according to Yahoo Finance.

Pressmaster/Shutterstock.com

Precigen (PGEN) is simply a biotechnology institution that has transitioned from a clinical-stage developer to a commercialized uncommon illness level pursuing the August 2025 support of Papzimeous for recurrent respiratory papillomatosis, positioning it arsenic a recently commercialized plus with important re-rating imaginable arsenic motorboat execution unfolds.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The cause targets a 27,000-patient US RRP colonisation and carries a $460,000 four-dose regimen delivered via buy-and-bill channels, but the aboriginal motorboat signifier is constrained by security sum variability, infirmary onboarding, and reimbursement friction contempt beardown doc enthusiasm.

Market expectations look importantly misaligned with real-world adoption, arsenic attraction is concentrated successful 100–150 specializer clinics treating a ample stock of high-severity patients, enabling businesslike acquisition and accelerated protocol adoption supported by KOL advocacy and expanding entreaty occurrence rates. Modeling suggests lone a fraction of patients are presently treated, yet blimpish projections bespeak astir 1,600–1,700 patients successful 2026 and astir 3,000 successful 2027, with dosing-based gross designation driving pronounced quarterly volatility and mounting up for important gross surprises.

This dynamic supports expectations for outsized quarterly beats of 100%+ to 300%+ successful 2026, imaginable EPS inflection into profitability, and aggregate valuation frameworks converging connected important upside done SOTP rerating, guardant net expansion, and NPV-based semipermanent currency travel imaginable crossed RRP and HPV indications.

Strategically, the level besides embeds meaningful acquisition optionality, with large-cap pharma specified arsenic Merck viewed arsenic imaginable acquirers fixed HPV oncology expansion, ex-US commercialization leverage, and manufacturing scale, supporting a semipermanent takeout communicative perchance valuing the institution adjacent $20 per stock by 2027 people premium.

Previously, we covered a bullish thesis connected CRISPR Therapeutics AG (CRSP) by MADD-Scientis successful March 2025, which highlighted Casgevy-driven commercialization, gene-editing pipeline optionality, and beardown reimbursement advancement supporting multi-billion-dollar semipermanent upside. CRSP’s banal terms has appreciated by astir 27.06% since our coverage. Magnus Ofstad shares a akin presumption but emphasizes Sarepta Therapeutics’ (SRPT) acquisition-driven rerating imaginable wrong uncommon illness leadership.